Literature DB >> 11287002

Dual Ser and Thr phosphorylation of CPI-17, an inhibitor of myosin phosphatase, by MYPT-associated kinase.

J A MacDonald1, M Eto, M A Borman, D L Brautigan, T A Haystead.   

Abstract

Phosphorylation of CPI-17 and PHI-1 by the MYPT1-associated kinase (M110 kinase) was investigated. M110 kinase is a recently identified serine/threonine kinase with a catalytic domain that is homologous to that of ZIP kinase (ZIPK. GST-rN-ZIPK, a constitutively active GST fusion fragment, phosphorylates CPI-17 (but not PHI-1) to a stoichiometry of 1.7 mol/mol. Phosphoamino acid analysis revealed phosphorylation of both Ser and Thr residues. Phosphorylation sites in CPI-17 were identified as Thr 38 and Ser 12 using Edman sequencing with (32)P release and a point mutant of Thr 38.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11287002     DOI: 10.1016/s0014-5793(01)02277-3

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  32 in total

Review 1.  Protein kinase network in the regulation of phosphorylation and dephosphorylation of smooth muscle myosin light chain.

Authors:  Katusya Hirano; Dmitry N Derkach; Mayumi Hirano; Junji Nishimura; Hideo Kanaide
Journal:  Mol Cell Biochem       Date:  2003-06       Impact factor: 3.396

2.  Integrin-linked kinase is responsible for Ca2+-independent myosin diphosphorylation and contraction of vascular smooth muscle.

Authors:  David P Wilson; Cindy Sutherland; Meredith A Borman; Jing Ti Deng; Justin A Macdonald; Michael P Walsh
Journal:  Biochem J       Date:  2005-12-15       Impact factor: 3.857

3.  Chemical genetics of zipper-interacting protein kinase reveal myosin light chain as a bona fide substrate in permeabilized arterial smooth muscle.

Authors:  Lori D Moffat; Shannon B A Brown; Michael E Grassie; Annegret Ulke-Lemée; Laura M Williamson; Michael P Walsh; Justin A MacDonald
Journal:  J Biol Chem       Date:  2011-08-31       Impact factor: 5.157

Review 4.  Signaling in muscle contraction.

Authors:  Ivana Y Kuo; Barbara E Ehrlich
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-02-02       Impact factor: 10.005

Review 5.  Mechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle Disorders.

Authors:  F V Brozovich; C J Nicholson; C V Degen; Yuan Z Gao; M Aggarwal; K G Morgan
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

6.  ZIPK mediates endothelial cell contraction through myosin light chain phosphorylation and is required for ischemic-reperfusion injury.

Authors:  Yiteng Zhang; Chenghai Zhang; He Zhang; Weiwei Zeng; Shuai Li; Caiping Chen; Xiaobin Song; Jie Sun; Zhiyuan Sun; Congcong Cui; Xiang Cao; Lirong Zheng; Pei Wang; Wei Zhao; Zhao Zhang; Yun Xu; Minsheng Zhu; Huaqun Chen
Journal:  FASEB J       Date:  2019-06-10       Impact factor: 5.191

7.  Targeting Pim Kinases and DAPK3 to Control Hypertension.

Authors:  David A Carlson; Miriam R Singer; Cindy Sutherland; Clara Redondo; Leila T Alexander; Philip F Hughes; Stefan Knapp; Susan B Gurley; Matthew A Sparks; Justin A MacDonald; Timothy A J Haystead
Journal:  Cell Chem Biol       Date:  2018-07-19       Impact factor: 8.116

8.  Differential signalling by muscarinic receptors in smooth muscle: m2-mediated inactivation of myosin light chain kinase via Gi3, Cdc42/Rac1 and p21-activated kinase 1 pathway, and m3-mediated MLC20 (20 kDa regulatory light chain of myosin II) phosphorylation via Rho-associated kinase/myosin phosphatase targeting subunit 1 and protein kinase C/CPI-17 pathway.

Authors:  Karnam S Murthy; Huiping Zhou; John R Grider; David L Brautigan; Masumi Eto; Gabriel M Makhlouf
Journal:  Biochem J       Date:  2003-08-15       Impact factor: 3.857

Review 9.  Smooth muscle signalling pathways in health and disease.

Authors:  H R Kim; S Appel; S Vetterkind; S S Gangopadhyay; K G Morgan
Journal:  J Cell Mol Med       Date:  2008-12       Impact factor: 5.310

10.  Phosphorylation of the myosin phosphatase inhibitors, CPI-17 and PHI-1, by integrin-linked kinase.

Authors:  Jing Ti Deng; Cindy Sutherland; David L Brautigan; Masumi Eto; Michael P Walsh
Journal:  Biochem J       Date:  2002-10-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.